News & Updates

Individuals with metabolic syndrome who are hospitalized for COVID-19 may have a greater risk for more severe COVID-19 disease, including an elevated risk of in-hospital mortality, acute respiratory distress syndrome (ARDS), and intensive care unit (ICU) admission, a recent prospective study showed.

Adding aspirin to usual care did not lead to a reduced mortality rate in patients hospitalized with COVID-19, according to a study by the RECOVERY* Collaborative Group.

There is no apparent increased risk of deep vein thrombosis (DVT) following receipt of the COVID-19 vaccine, according to a study presented at ASH 2021.

In the treatment of patients with COVID-19, administering remdesivir within 5 days of symptom onset appears to reduce the risk of progression to severe disease, as shown in a study.

In the phase II proof-of-concept CATALYST trial comparing the GM-CSF* inhibitor namilumab and the TNF** inhibitor infliximab against usual care (UC), namilumab, but not infliximab, demonstrated signals for reducing inflammation in hospitalized patients with COVID-19 pneumonia.

Nonsmall cell lung cancer (NSCLC) with mutations in the KRAS gene show a unique genetic and clinical profile in Asian patients relative to Western counterparts, according to a recent study.

Treatment with the selective serotonin reuptake inhibitor fluvoxamine may prevent hospitalization in outpatients presenting with symptoms of COVID-19 who have a high risk for disease progression, according to results of the TOGETHER trial.